Covid-19 Updates: India Reports 1.2 Lakh New Cases, 3,380 Deaths In Last 24 Hours
Social distancing markers on the floor at New Delhi railway station in India. Photographer: Prashanth Vishwanathan/Bloomberg

Covid-19 Updates: India Reports 1.2 Lakh New Cases, 3,380 Deaths In Last 24 Hours

Latest First
  • Oldest First

India continued to add fewer coronavirus cases, giving respite to its overburdened healthcare system which has been creaking under the pandemic’s strain ever since infections rose across the world’s second-most infected nation.

Nearly 1.2 lakh people tested positive for the deadly pathogen in the last 24 hours, according to the Health Ministry’s update as of 8 a.m. on June 5. Recoveries during the same period remained significantly higher at 1.97 lakh. As a result, active infections fell to 15.52 lakh.

Daily fatality rate rose above 3,000, with 3,380 patients succumbing to the illness. That took the total Covid-19 related death toll to 3.44 lakh.

Key Figures

  • Total number of confirmed coronavirus cases: 2,86,94,879.
  • Active cases: 15,55,248.
  • Total patients cured or discharged: 2,67,95,549.
  • Deaths: 3,44,082.
  • Number of fresh cases in last 24 hours: 1,20,529.
  • One-day recoveries: 1,97,894.
  • One-day deaths: 3,380.

BMC In Talks With Dr Reddy's For Vaccine, Disqualifies Nine Other Bids

Mumbai’s civic body disqualified nine suppliers who had applied for its global tender to procure one crore Covid-19 vaccines citing lack of proper documentation.

The Brihanmumbai Municipal Corporation, however, said it’s in active talks with Dr Reddy’s Laboratories Ltd., which distributes the Sputnik vaccine in India. On an experimental basis, some stocks of Sputnik vaccine will be given to BMC by the end of June 2021, it said.

SII Gets Nod To Make Sputnik V

Serum Institute of India has received the Indian drug regulator’s nod to make Covid-19 vaccine Sputnik V in the country, PTI reported. The Pune-based firm can manufacture the vaccine for examination, test and analysis.

Serum Institute, the report said, has collaborated with Russia’s Gamaleya Research Institute of Epidemiology and Microbiology to develop the vaccine at its licensed facility in Hadapsar, Pune.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.